Bruker has signed an agreement to acquire the preclinical imaging business of Oncovision, a leading provider of innovative imaging medical devices used for the diagnosis of cancer. Financial terms of the agreement were not disclosed.

For the past five years, Bruker and Oncovision have partnered on an exclusive marketing agreement for Albira™ PET/SPECT/CT systems, and have developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology for highest full field-of-view PET resolution and sensitivity.

“I am very pleased to announce that Oncovision pre-clinical group will be joining the Bruker family. Our two companies share a passion for leading imaging technology and a commitment to innovation that will be better served through this acquisition,” said Ignasi Vivas, Oncovision CEO. “Through the significant resources that Bruker will bring to bear through this acquisition, I am confident that the acceptance of Oncovision’s pre-clinical technology will be accelerated.